AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

MicroRNA expression profiles for diagnosis and microRNA based therapeutics for Alzheimer's disease and related dementias

Summary: John F. Crary, M.D., Ph.D..

Technology Benefits: Could guide development of a highly targeted therapyPotential therapy may have minimal side effects, as microRNAs target specific genes for regulationPersistent synthetic microRNAs can be delivered to specific brain regions to avoid off-target effects in other tissuesPatent information:Tech Ventures Reference: IR CU12162

Technology Application: Identifies gene expression changes that confer risk for neurodegeneration Targeted synthetic microRNAs for treatment of neurodegenerationNovel in vitro assays for drug screens that target tau expresssionNovel transgenic animals for drug screens that target tau expressionGenetic markers for Alzheimer's disease diagnosisGenetic markers for assessing an individual's risk for development of age-related tauopathy

Detailed Technology Description: John F. Crary, M.D., Ph.D..

*Abstract: None

*Inquiry: Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR: CU12162

*Principal Investigator

*Publications: I. Santa-Maria, A. Haggiagi, XM Liu, J. Wasserscheid, P. T. Nelson, K. Dewar, L.N. Clark, J. F. Crary. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol, Nov;124(5):693-704.

Country/Region: USA

For more information, please click Here